第三条 公司根据相关法律法规要求及业务经营发展需要，不定期召开专门 会议，专门会议由半数以上独立董事出席或委托出席方可举行。 第四条 专门会议由过半数独立董事共同推举一名独立董事担任召集人，负 责召集和主持；召集人不履职或者不能履职时，两名及以上独立董事可以自行召 集并推举一名代表主持。 独立董事专门会议议事规则 福建青松股份有限公司 独立董事专门会议议事规则 第一条 为进一步完善福建青松股份有限公司（以下简称"公司"）的法人 治理结构、提升规范运作水平，充分发挥独立董事在公司治理中的作用，维护公 司整体利益，保护中小股东及利益相关者的合法权益，根据《中华人民共和国公 司法》《上市公司独立董事管理办法》《上市公司治理准则》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等有关法律法规、规章、规范性文件和《福建青松股份有 限公司章程》（以下简称《公司章程》）的规定，并结合公司实际情况，制定本 规则。 第二条 独立董事专门会议（以下简称"专门会议"）是指全部由公司独立 董事参加的会议。独立董事是指不在公司担任除董事外的其他职务，并与公司及 公司主要 ...

Financial Performance - The company reported a net profit of negative value for the year 2023, with measures for improving profitability detailed in the management discussion section[2]. - The company's operating revenue for 2023 was ¥1,969,494,717, a decrease of 32.49% compared to ¥2,917,366,476 in 2022[20]. - The net profit attributable to shareholders was -¥68,341,309.97, showing a significant improvement of 90.79% from -¥742,420,713.32 in the previous year[20]. - The net cash flow from operating activities was ¥156,604,754.71, down 54.03% from ¥340,636,749.11 in 2022[20]. - The total assets at the end of 2023 were ¥2,371,146,800.46, a decrease of 26.41% from ¥3,194,595,271.44 at the end of 2022[20]. - The company reported a basic earnings per share of -¥0.1323, improving by 90.79% from -¥1.4372 in 2022[20]. - The weighted average return on equity was -5.08%, an improvement of 37.17% from -42.25% in the previous year[20]. - The company reported a total of ¥14,001,315.12 in non-recurring losses for 2023, compared to gains of ¥16,623,287.54 in 2022[26]. - The company achieved a revenue of CNY 196,131.42 million, a year-on-year decrease of 5.63%, with a gross margin of 11.74%, an increase of 7.35 percentage points[97]. - The company reported a net profit attributable to shareholders of CNY -5,034.26 million, a year-on-year increase of 78.12%[97]. Corporate Governance - The company held 9 board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[180]. - The company established a performance evaluation system linking senior management's performance to their compensation, ensuring transparency in hiring practices[182]. - The company disclosed information accurately and timely, designating a specific website for investors to access relevant information[184]. - The company maintained independence from its controlling shareholder, with no reliance on their assets for operations[187]. - The company has a complete and independent business system for R&D, production, and sales, ensuring no competition with the controlling shareholder[188]. - The company operates an independent financial department, with no shared bank accounts with major shareholders[192]. - The annual general meeting had a participation rate of 20.84% on May 26, 2023, reflecting shareholder engagement[193]. - The first temporary shareholders' meeting in 2023 had a participation rate of 20.62% on August 10, 2023[193]. - The second temporary shareholders' meeting in 2023 had a participation rate of 20.10% on November 21, 2023[193]. - The company is focused on maintaining compliance with independent director regulations following recent board changes[197]. - The company’s strategic committee will need to address the absence of independent directors after Dong Hao's resignation[197]. - The company continues to prioritize governance and leadership stability amid recent changes in its executive team[198]. Business Operations - The company has a total of six wholly-owned subsidiaries, including Nuo Si Bei Cosmetics Co., Ltd. and Guangdong Nuo Si Bei Health Care Products Co., Ltd.[13]. - The company operates primarily in the cosmetics industry, focusing on the design, research, and manufacturing of facial masks, skincare products, and wet wipes[30]. - The subsidiary, Norsbel, accounted for 99.59% of the company's consolidated revenue during the reporting period[31]. - Norsbel focuses on ODM business for cosmetics, providing comprehensive services from design to manufacturing for downstream brand owners[32]. - The company has established long-term partnerships with global suppliers such as BASF and Ashland, enhancing its supply chain efficiency and product quality[86]. - The company has built stable partnerships with numerous well-known domestic and international cosmetic brands[57]. - The company has a diverse product line, including specialized cosmetics, cleaning wipes, and facial masks[48]. - The company has implemented a customer-driven sales model, producing based on confirmed orders[56]. - The company has received recognition as an excellent supplier from various brand clients, enhancing its market reputation[57]. - The company has established a comprehensive quality management system certified by ISO22716, ISO13485, and ISO9001, ensuring product safety and efficacy[92]. Market Trends and Industry Analysis - In 2023, the global beauty market grew to $625.7 billion, with a projected increase to $646.2 billion in 2024, reflecting a year-on-year growth of 3.28%[61]. - The retail sales of cosmetics in China reached ¥414.2 billion in 2023, marking a 5.1% increase compared to the previous year[63]. - The average disposable income per capita in China was ¥39,218 in 2023, with a nominal growth rate of 6.3% and a real growth rate of 6.1%[62]. - The number of licensed cosmetics manufacturers in China reached 7,114 in 2023, with 4,024 located in Guangdong, accounting for approximately 55%[64]. - The market concentration of the top 10 cosmetics brands in China was 16.1% in 2023, a decrease of 2.2 percentage points from 2022, indicating intensified competition[64]. - The online sales channel accounted for 50.75% of the Chinese cosmetics market in 2023, with a market size of ¥404.59 billion, while offline sales accounted for 49.25% with a size of ¥392.61 billion[69]. - The male skincare market in China was valued at ¥11.824 billion in 2023, with a projected annual growth rate of 2.9% over the next five years[68]. - The demand for OEM/ODM services is increasing due to the emergence of new cosmetic brands that lack production capabilities, creating opportunities for competitive contract manufacturers[67]. - The cosmetics industry in China is experiencing a shift towards rational consumption, with consumers prioritizing product quality and service experience[66]. - The regulatory environment for the cosmetics industry is becoming stricter, which may pose short-term challenges but will benefit long-term industry health[70]. Research and Development - The company has a professional R&D team of over 180 people, continuously developing new products to meet diverse client needs[79]. - The company has received multiple awards, including the 2022 Top 10 Chinese Cosmetics Manufacturers and the 2023 Annual Influential ODM Award[58]. - The company has successfully developed over 1,000 new formulas during the reporting period, showcasing its efficiency in technology research and product innovation[89]. - The company has a total of 134 valid patents, including 36 invention patents, 82 utility model patents, and 16 design patents, which support its differentiated product positioning[91]. - The company is actively collaborating with universities and research institutions to enhance its technological innovation capabilities[79]. - The company is exploring the application of active extracts from Tremella fuciformis in facial mask formulations, aiming to expand its product line and market competitiveness[129]. - The company aims to enhance its product offerings in the "natural, efficient, and healthy" category through ongoing R&D efforts[129]. - The company has initiated several R&D projects, including the development of a natural, gentle makeup remover oil, which is currently in the technical design phase[129]. Strategic Initiatives and Future Outlook - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves[3]. - The company aims to enhance its market expansion and product development strategies in the cosmetics sector[31]. - Future outlook includes continued investment in new product development and technology to strengthen market position[31]. - The company is actively pursuing new projects, such as the enzyme production line expansion, with environmental approvals obtained[80]. - The company plans to enhance R&D investment and new product development to strengthen its market position and sustainable profitability[151]. - In 2024, the company aims to focus on cost control and structural adjustments to improve core competitiveness in the cosmetics business[152]. - The company will implement measures to optimize production management, aiming to reduce costs and improve efficiency[155]. - The company intends to strengthen its technological innovation and enhance industry competitiveness through advanced production technologies[159]. - The company is actively exploring diversification in the cosmetics and consumer goods industry through mergers and acquisitions[161]. Risks and Challenges - The company has acknowledged uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the past three years[21]. - The company faces risks related to macroeconomic conditions and raw material price fluctuations, which could impact profitability[162]. - The company is at risk of operational performance decline and sustained losses if market conditions do not improve or if it fails to secure new orders[172]. - The cosmetics industry is experiencing increased competition, which may impact the company's sales if it fails to meet customer demands[166]. - The company is focused on enhancing safety and environmental management to reduce operational risks associated with production processes[168].

福建青松股份有限公司 关于营业收入扣除事项的 专项核查意见 大华核字[2024]0011008742 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 二、 营业收入扣除情况明细表 1-1 福建青松股份有限公司 关于营业收入扣除事项的专项核查意见 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | | 一、 关于营业收入扣除事项的专项核查意见 1-2 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 关 于 营 业 收 入 扣 除 事 项 的 专 项 核 查 意 见 我们认为，青松股份 2023 年度营业收入扣除事项明细表中的财 务信息在所有重大方面按照监管机构上市规则的规定编制以满足监管 要求。 大华核字[2024] 0011008742号 福建青松股份有限公司 ...

福建青松股份有限公司 内部控制鉴证报告 大华核字[2024] 0011008739 号 大 华 会 计 师 事 务 所 ( 特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 福建青松股份有限公司 内部控制鉴证报告 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 内部控制鉴证报告 1-2 二、 福建青松股份有限公司 2023 年度内部控制评 价报告 1-17 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 内 部 控 制 鉴 证 报 告 大华核字[2024] 0011008739 号 福建青松股份有限公司全体股东： 我们接受委托，鉴证了后附的福建青松股份有限公司（以下简 称"青松股份"）管理层编制的《2023 年度内部控制评价报告》涉 及的 2023 年 12 月 31 日与财务报表相关的内部控制有效性的认定。 ...

独立董事 2023 年度述职报告 福建青松股份有限公司 独立董事 2023 年度述职报告 各位股东及股东代表： 本人作为福建青松股份有限公司（以下简称"公司"或"青松股份"）的独 立董事，在 2023 年度严格按照《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司独立董事管理办法》、 《深圳证券交易所创业板股票上市规则》（以下简称《上市规则》）、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称《规 范运作指引》）等相关法律法规、规章、规范性文件以及《公司章程》和《独立 董事工作制度》的相关规定和要求，不受公司大股东、实际控制人以及其他与公 司存在利害关系的单位或个人的影响，维护公司和全体股东的合法权益，尤其是 广大中小股东的合法权益。 在 2023 年度工作中，本人诚实、勤勉、独立地履行职责，以独立、公正的 精神对公司重大经营事项、法人治理等方面的问题积极献计献策，并对董事会的 相关事项发表了独立意见。现就本人 2023 年度履行职责情况报告如下： 一、个人基本情况 唐清泉：1960 年出生，中国国籍，无境外永久居 ...

2023 年度内部控制评价报告 福建青松股份有限公司 2023 年度内部控制评价报告 福建青松股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合福建青松股份有限公司（以下简 称"公司"或"本公司"）各项内部控制制度和评价办法，在内部控制日常监督 和专项监督的基础上，我们对公司 2023 年 12 月 31 日（内部控制评价报告基准 日）的内部控制体系建设及运行状况有效性进行评价，具体如下： 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。管理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性 ...

福建青松股份有限公司 章 程 （本章程经第五届董事会第八次会议审议修订，尚需公司股东大会审议通过） 二〇二四年四月 | 第一章 | 总 | 则 1 | | --- | --- | --- | | 第二章 | | 经营宗旨和范围 2 | | 第三章 | | 股份 2 | | 第一节 | | 股份发行 2 | | 第二节 | | 股份增减和回购 3 | | 第三节 | | 股份转让 5 | | 第四章 | | 股东和股东大会 5 | | 第一节 | | 股东 6 | | 第二节 | | 股东大会的一般规定 8 | | 第三节 | | 股东大会的召集 10 | | 第四节 | | 股东大会的提案与通知 11 | | 第五节 | | 股东大会的召开 13 | | 第六节 | | 股东大会的表决和决议 16 | | 第五章 | | 董事会 20 | | 第一节 | | 董事 20 | | 第二节 | | 董事会 23 | | 第六章 | | 总经理和其他高级管理人员 28 | | 第七章 | | 监事会 30 | | 第一节 | | 监事 30 | | 第二节 | | 监事会 31 | | 第八章 | | 财务会计制度 ...

第五届董事会第八次会议决议公告 证券代码：300132 证券简称：青松股份 公告编号：2024-016 福建青松股份有限公司 第五届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 福建青松股份有限公司（以下简称"公司"或"青松股份"）第五届董事会 第八次会议于 2024 年 4 月 14 日以直接送达或电子邮件方式发出会议通知，本次 会议于 2024 年 4 月 25 日下午在青松股份中山分公司会议室以现场方式召开。会 议应出席董事 6 名，实际出席董事 6 名，会议由董事长范展华先生主持，董事会 秘书、监事及其他高级管理人员列席了本次会议。会议召开符合《中华人民共和 国公司法》（以下简称《公司法》）等法律法规以及《福建青松股份有限公司章程》 （以下简称《公司章程》）的规定，会议召开合法、有效。 二、董事会会议审议情况 经与会董事认真审议，并以记名投票表决方式通过如下决议： 1、审议通过《关于<2023 年度总经理工作报告>的议案》； 与会董事一致认为，《2023 年度总经理工作报告》真实、准确地反映了公司 经 ...

一、关于《2023 年度利润分配预案》的审核意见 2023 年度利润分配预案为：不派发现金红利，不送红股，不以公积金转增 股本。 第五届董事会第一次独立董事专门会议审核意见 福建青松股份有限公司 第五届董事会第一次独立董事专门会议审核意见 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证 券法》（以下简称《证券法》）、《上市公司独立董事管理办法》《深圳证券交易所 创业板股票上市规则》《上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《福建青松股份有限公司章程》（以下简称《公司章程》）及《独立董事工 作制度》等有关规定，福建青松股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日以现场方式召开公司第五届董事会第一次独立董事专门会议。 本次会议应到独立董事 3 人，实际参会独立董事 3 人，独立董事共同推举唐 清泉先生为本次独立董事专门会议的召集人和主持人。本次会议的召集、召开符 合有关法律、行政法规、部门规章、规范性文件及《公司章程》的规定。 基于独立、审慎、客观的立场，本着对公司及全体股东负责的态度，公司独 立董事就拟提交公司第五届董事会第八次会议审议的《关于< ...

福建青松股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字[2024] 0011008741 号 大华会计师事务所 ( 特 殊 普 通 合 伙 ) 控股股东及其他关联方资金占用情况的专项说明 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项 说明 1-2 二、 附件：福建青松股份有限公司 2023 年度非经 营性资金占用及其他关联资金往来情况汇总 表 1-1 Da Hua Certified Public Accountants（Special General Partnership） 福建青松股份有限公司 根据中国证券监督管理委员会发布的《上市公司监管指引第8号 ——上市公司资金往来、对外担保的监管要求》(证监会公告 [2022]26号)和深圳证券交易所《深圳证券交易所创业板上市公司自 律监管指南第1号——业务办理》的规定，就青松股份编制的2023年 度非经营性资金占用及其他关联资金往来情况汇总表（以下简称" 汇总表"）出具专项说明。 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [1000 ...